Skip to main content
Clinical Trials/NCT06326489
NCT06326489
Recruiting
Phase 4

Evaluating the Efficacy and Quality of Life Impact of Transitioning to Advanced Hybrid Closed-Loop Insulin Pump Therapy in Romanian Children With Type 1 Diabetes Mellitus

ELIAS Emergency University Hospital1 site in 1 country30 target enrollmentMarch 11, 2024

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Diabetes Mellitus, Type 1
Sponsor
ELIAS Emergency University Hospital
Enrollment
30
Locations
1
Primary Endpoint
Variations in HbA1c
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The proposed study aims to demonstrate the potential benefits of transitioning T1DM children from predictive low glucose suspend insulin pump therapy to advanced hybrid closed-loop insulin pump therapy in Romania. Primary Outcome: Variations in HbA1c between baseline visit (V1 - 740G) and assessment visit following three months of 780G insulin pump therapy (V2 - 780G).

Secondary Outcomes: changes in insulin requirements, time in range (TIR) levels, time below range (TBR), coefficient of variation (CV), frequency of severe hypoglycemic and hyperglycemic events requiring hospitalization, and PedsQL SF15 questionnaire scores.

Registry
clinicaltrials.gov
Start Date
March 11, 2024
End Date
November 30, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
ELIAS Emergency University Hospital
Responsible Party
Principal Investigator
Principal Investigator

Ioacara Sorin

Assoc. Prof. Dr.

ELIAS Emergency University Hospital

Eligibility Criteria

Inclusion Criteria

  • Age 7 years or older at baseline
  • Diagnosis of type 1 diabetes
  • Current use of a predictive low glucose suspend insulin pump (740G)
  • At least 30% of subjects must have an HbA1c \> 7,5% (58 mmol/mol)

Exclusion Criteria

  • Age \< 7 years or ≥ 18 years at baseline
  • Diabetes duration \< 1 year at baseline
  • HbA1c ≤ 7% (53 mmol/mol)
  • Not meeting the Romanian national standards for closed-loop insulin pump therapy
  • Other criteria deemed inappropriate by the principal investigator (to be documented)

Outcomes

Primary Outcomes

Variations in HbA1c

Time Frame: Three months

Variations in HbA1c between baseline visit (V1 - 740G) and assessment visit following three months of 780G insulin pump therapy (V2 - 780G)

Secondary Outcomes

  • changes in insulin requirements(Three months)
  • changes in time below range (TBR)(Three months)
  • changes in coefficient of variation (CV)(Three months)
  • changes in time in range (TIR) levels(Three months)
  • changes in frequency of severe hypoglycemic and hyperglycemic events requiring hospitalization(Three months)
  • changes in The Pediatric Quality of Life Inventory™ 4.0 Short Form 15 Generic Core Scales questionnaire scores(Three months)

Study Sites (1)

Loading locations...

Similar Trials